The therapeutic dilemma: How to use short-acting PDE5 inhibitor drugs

International Journal of Andrology, Supplement

Volumn 28, Issue 2, 2005, Pages 69-73

  Fabbri, Andrea ^a   Aversa, A ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Erection; Nitric oxide; Phosphodiesterase type 5 inhibitors; Therapy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; CYCLIC GMP; NITRIC ACID DERIVATIVE; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; VARDENAFIL;

BRADYCARDIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; FOOD DRUG INTERACTION; GASTROESOPHAGEAL REFLUX; HEART INFARCTION; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; NOSE CONGESTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RHINITIS; SEXUAL INTERCOURSE; SKIN MANIFESTATION; SMOOTH MUSCLE RELAXATION; TACHYPHYLAXIS; VASODILATATION; VISUAL IMPAIRMENT;

EID: 28344454809     PISSN: 13504908     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2605.2005.00589.x     Document Type: Conference Paper

References (26)

1. Arruda-Olson, A. D., Mahoney, D. W., Nehra, A., Leckel M. & Bellikka P. A. (2002) Cardiovascular effects of sildenafil during. The Journal of American Medical Association 287, 719-725.
2. Aversa, A. & Fabbri, A. (2001) New oral agents for erectile dysfunction: what is changing in our practice? Asian Journal of Andrology 3, 175-179.
3. Aversa, A., Isidori, A. & Fabbri, A. (1996) Anxiety-induced failure in erectile response to intracorporeal prostaglandin-El in non-organic male impotence: a new diagnostic approach. International Journal of Andrology 19, 307-313.
4. Aversa, A., Pili, M., Fabbri, A., Spera, E. & Spera, G. (2004) Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition. Journal of Endocrinological Investigation 27, 192-206.
5. Basu, A. & Ryder, R. E. (2004) New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs 64, 2667-2688.
6. Behr-Roussel, D., Gorny, D., Mevel, K., Eaisey S., Bernabe S., Burgess G., et al. (2005) Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. European Urology 47, 87-91.
7. Brindis, R. G. & Kloner, R. A. (2003) Sildenafil in patients with cardiovascular disease. American Journal of Cardiology 92, 26M-36M.
8. Brock, G., Nehra, A., Lipshultz, L. I., Karlin G. S., Gleave M., Seger H. et al. (2003) Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. Urology 170 (4 Pt 1), 1278-1283.
9. Campbell, H. E. (2005) Clinical monograph for drug formulary review: erectile dysfunction agents. Journal of Managed Care Pharmacy 11, 151-171.
10. Carson, C. C. (2003) Long-term use of sildenafil. Expert Opinion Pharmacotherapeutic 4, 397-405.
11. DeBusk, R. F., Pepme, C. J., Glasser, D. B., Shillsky A., De Riesthal H. & Sweeney M. (2004) Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. American Journal of Cardiology 93, 147-153.
12. Fabbri, A., Aversa, A. & Isidori, A. (1999) Sildenafil and erectile dysfunction. Journal of Endocrinological Investigation 22, 486-492.
13. Ghofrani, H. A., Voswinckel, R., Reichenberger, F., Olschewsky H., Haredza P., Karadas P. et al. (2004) Differences in hemodynamic and oxygenation response to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. Journal of the American College of Cardiology 44, 1488-1496.
14. Goldstein, I., Young, J. M., Fischer, J., Bangerter K., Segerson T., Taylor T. et al. (2003) Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 26, 777-783.
15. Hellstrom, W. J. (2003) Vardenafil: a new approach to the treatment of erectile dysfunction. Current Urology Report 4, 479-487.
16. Jackson, G., Benjamin, N., Jackson, N. et al. (1999) Effects of sildenafil citrate on human hemodynamics. American Journal of Cardiology 83, 13C-20C.
17. Keating, G. M. & Scott, L. J. (2004) Spotlight on vardenafil in erectile dysfunction. Drugs and Aging 21, 135-140.
18. Kloner, R. A. (2000) Sex and the patient with cardiovascular risk factors: focus on sildenafil. American Journal of Medicine 109, 13S-21S; discussion 29S-30S.
19. Klotz, T., Sachse, R., Heidrich, A., Sockenhovel F., Rohde G., Wensing G. et al. (2001) Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World Journal of Urology 19, 32-39.
20. Lugg, J. A., Gonzales-Cadavid, N. F. & Rajfer, J. (1995) The role of nitric oxide in erectile function. Journal of Andrology 16, 2-4.
21. Mercapide, J., Santiago, E., Alberdi, E., Martinez-Iqujo SS. et al. (1999) Contribution of phosphodiesterase isoenzymes and cyclic nucleotide efflux to the regulation of cyclic GMP levels in aortic smooth muscle cells. Biochemistry and Pharmacology 58, 1675-1683.
22. Seftel, A. D. (2004) Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clinical Cardiology 27, 114-119.
23. Stark, S., Sachse, R., Liedl, T., Hensen S., Rohde G., Wensing G. et al. (2001) Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. European Urology 40, 181-188; discussion 180-190.
24. Takimoto, E., Chamaon H.C., Li M., Belardi D., Ren S., Rodriguez E.R., et al (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nature Medicine 11, 214-222. Epub 2005 Jan 23.
25. Thadani, U., Smith, W., Nash, S., Bittar N., Classer S., Narayan P., et al. (2002) The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. Journal of the American College of Cardiology 40, 2006-2012.
26. Zusman, R. M., Morales, A., Classer, D. B., Osterloh I.H. (1999) Overall cardiovascular profile of sildenafil citrate. American Journal of Cardiology 83, 35C-44C.